Aliasger K. Salem is the Associate Vice President for Research at the University of Iowa and Bighley Chair and Professor of Pharmaceutical Sciences at the University of Iowa College of Pharmacy.
[4] Prior to joining the University of Iowa in 2004, he was a postdoctoral fellow at the Johns Hopkins School of Medicine and completed his PhD at the School of Pharmacy and Pharmaceutical Sciences at the University of Nottingham in the UK.
[5] Salem led the Experimental Therapeutics (ET) program at the Holden Comprehensive Cancer Center[6] from 2012 to 2024 and serves as co-director of the Nanotoxicology Core at the Environmental Health Sciences Research Center.
[9] Aliasger Salem has been or is a member of a number of grant review study sections including panels for the American Cancer Society,[10] the National Institutes of Health, the National Science Foundation, and the Department of Defense (DoD): Congressionally Directed Medical Research Programs (CDMRP) Prostate and Breast Cancer Research Programs.
[11] Salem's research interests [12][13] include nanotechnology,[14] microfabrication, particle and drug delivery systems,[15] implantable chips,[16] the design of gene delivery systems,[17][18][19] regenerative medicine,[20][21] and the development of vaccines.